FDA Issues Draft Guidance on Biovailability Trials

Drug Industry Daily
Sponsors of bioavailability trials should be prepared to show that any differences in the rate or extent of absorption compared with an existing drug won’t affect the safety or efficacy of the candidate drug, the FDA said in a new draft guidance issued Monday.

To View This Article:


Subscribe To Drug Industry Daily